Sample collection and isolation
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study | Gordon NS, et al | BJU international | Jan. 2022
Gordon NS, Baxter LA, Goel A, Arnold R, Kaur B, Liu W, et al. Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. BJU International. 2022;129(1):32-4. Nonacus products: Oncology Overview: Accumulating evidence implies the utility of DNA-based urine biomarkers for initial detection of bladder cancer (BC) and surveillance of non-muscle-invasive BC.…
Read MoreEnhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR | Ghorashian S, et al | Nature medicine | Sep. 2019
Nonacus Products: Cell3 Target: Oncology Abstract Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL), but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19− clones. Some factors, including the choice…
Read More